GleamWall
中文EN

CTXR Citius Pharmaceuticals, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1506251 · Fiscal year ends 09/30

Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-11.1%
TTM EPS YoY64.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-70.3%
ROA-34.3%
ROIC (approx.)-89.3%
Asset turnover—

Leverage & solvency

Liabilities / assets46.6%
Debt / equity0.00x
Current ratio0.84x
Interest coverage-127.24x

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-8.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q3*2026-06-302026Q2*2026-03-312026Q1*2025-12-312025Q4*2025-09-302025Q3*2025-06-302025Q22025-03-312025Q12024-12-312024Q4*2024-09-30
Income statement
Revenue$1.49M$1.67M$3.94M—————
Cost of revenue$491,843$328,878$789,208—————
Gross profit$1.00M$1.34M$3.15M—————
R&D expense$1.05M$1.63M$1.60M$1.64M$1.62M$3.77M$2.13M$2.91M
SG&A expense$6.15M$26.39M$5.72M$3.91M$4.45M$4.79M$5.39M$5.49M
Operating income-$11.73M-$32.19M-$9.02M-$8.44M-$8.79M-$11.26M-$10.04M-$11.05M
Interest expense$198,333$33,031$155,538$95,520$172,262———
Pretax income-$12.03M-$28.34M-$9.13M-$8.48M-$8.94M-$11.25M-$10.02M-$10.93M
Income tax-$107,347-$231,210$264,240$264,240$264,240$264,240$264,240$144,000
Net income-$8.86M-$21.23M-$8.22M-$7.96M-$8.79M-$11.51M-$10.28M-$11.08M
EBITDA———————-$11.05M
EPS (basic)-0.34-0.95-0.38—-0.80-1.27-1.30—
EPS (diluted)-0.34-0.95-0.38—-0.80-1.27-1.30—
Weighted avg. shares (diluted)26.17M22.38M21.50M—11.01M8.58M7.49M—
Balance sheet
Cash & equivalents$17.01M$4.59M$7.72M$4.25M$6.09M$26,410$1.10M$3.25M
Receivables$686,235$1.08M$4.05M—————
Inventory$22.63M$22.66M$22.64M$22.29M$17.21M$15.34M$14.38M$8.27M
Current assets$43.33M$31.69M$37.95M$27.93M$24.61M$18.37M$18.33M$14.22M
Goodwill$9.35M$9.35M$9.35M$9.35M$9.35M$9.35M$9.35M$9.35M
Total assets$142.26M$132.54M$140.39M$130.94M$127.68M$121.48M$120.70M$116.65M
Current liabilities$51.65M$55.02M$38.21M$44.91M$51.84M$49.88M$44.81M$35.81M
Total liabilities$66.35M$63.46M$46.92M$53.41M$60.12M$57.91M$51.78M$42.55M
Shareholders' equity$66.61M$61.54M$79.96M$67.55M$65.06M$60.66M$65.41M$70.08M
Shares outstanding27.45M22.38M22.38M18.07M14.48M8.76M7.73M7.25M
Cash flow statement
Operating cash flow-$8.68M-$1.30M-$13.01M-$11.88M-$5.41M-$4.54M-$4.73M-$5.91M
Investing cash flow-$2.00M-$600,000-$4.40M—————
Financing cash flow$23.09M-$1.23M$20.88M$15.79M$11.47M$3.47M$2.57M-$3.75M
Depreciation & amortization———————$0
Stock-based compensation$3.81M$3.79M$4.28M$2.89M$2.72M$2.70M$2.52M$2.64M

Free plan shows the latest 8 periods; Pro shows all 63 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.